Wellcome Institutional Strategic Support Fund
UCL is the recipient of an Institutional Strategic Support Fund (ISSF) award from the Wellcome Trust. This fund enables us to invest in and support UCL research in the life and biomedical sciences. The UCL Wellcome ISSF supports areas of high strategic need across UCL, which are within the Wellcome research remit. ISSF funds are distributed across the following schemes:
1. Flexible support awards
There is an annual call for Flexible Funding awards. These awards are focused on strategic support for the establishment of new research groups, programmes and/or laboratories and for early- and mid-career researchers who currently hold a Fellowship award at UCL and require additional research support beyond the end of their fellowship funding.
The next call is anticipated to be in September 2018.
If your questions are not answered on the link above please contact Sinéad Kennedy (Director of Research Coordination and Planning, UCL Office of the Vice-Provost (Health)).
2. Translational Research
UCL’s Translational Research Group (TRG) provides integrated support to facilitate the translation of UCL’s basic and clinical research into therapies, techniques and medical products with therapeutic value.
The ISSF is contributing towards:
- UCL’s Therapeutic Acceleration Support (TAS) Fund which aims to accelerate the transition from discovery science to the early stages of therapeutic development, by providing responsive and flexible funding to overcome specific challenges in translational progression. For further information about this fund, please contact Simon Eaglestone (Translational Research Manager, UCL Translational Research Office)
- The Drug Discovery Group (DDG) to sustain UCL’s ability to translate novel biological insight/targets into robust drug discovery programs that are attractive to industry and potential follow-on funding.
- Therapeutic Innovation Networks (TINs) in biologicals and small-molecule discovery to maximise our abilities to deliver translation in this area. The networks created will collate the collective capability in each area, then develop activities (e.g.workshops and training) to support networking and coordinated and collaborative activities. They also provide strategic oversight on partnership development between academia, NHS and industry to accelerate the provision of new therapeutics and identify and develop educational programmes to enhance the innovation process.
3. Interdisciplinary research and discipline hopping
The awards target UCL’s strategic research priorities to support interdisciplinary and ‘discipline hopping’ research through training in new disciplines, testing or developing new methods, or performing proof of concept studies between the biomedical faculties in the UCL School of Life and Medical Sciences (SLMS), and across UCL.
4. Public engagement (PE) and patient public involvement (PPI)
The ISSF will support patient and public involvement (PPI) through the collaborative efforts of the UCL Public Engagement Unit and the NIHR programme for Patients and the Public in Research by establishing closer relationships across UCL and its partner PPI programmes of the three Biomedical Research Centres (BRCs) at:
This project aims to maximise the impact of research from UCL SLMS by further developing and innovating in the area of learning and development for researchers.
For further information please contact Niccola Hutchinson-Pascal (Project Manager, UCL Public Engagement)